AstraZeneca and Charles River presentation on simplifying outsourced preclinical safety studies31 July 2018
We are pleased to make available the presentation ‘Use of a Collaborative Tool to Simplify the Outsourcing of Preclinical Safety Studies: an insight into the AstraZeneca-Charles River Labs strategic relationship’ by AstraZeneca and Charles River, as delivered at Bio2Business and the World Preclinical Congress. The presentation describes how they used iTraX™ to simplify the outsourcing of preclinical safety studies, as published in Drug Discovery Today.
Frederic Martin, Senior Externalisation Specialist, Alliance & Project Management at AstraZeneca, said: “By using iTraX as our main collaborative tool to manage strategic outsourcing with CRL, we were able to visualise and share our portfolio and all studies at different stages of the outsourcing process. We could also benefit from all the new possibilities iTraX offers in refining, simplifying and improving our processes.”
David Hollinshead, Technical Director at Elixir Software comments, “It’s gratifying to see iTraX become an indispensable tool for study portfolio management, covering study design, planning/costing, scheduling, and also tracking delivery”. He adds, “The benefits ascribed by AstraZeneca and CRL immediately resonate with other company internal and external study management needs. We are now helping many new customers maximise value through effective study management”.
Contact us to find out how Elixir and iTraX™ can enhance your project.